Increased survival rate by local release of diclofenac in a murine model of recurrent oral carcinoma.

Despite aggressive treatment with radiation and combination chemotherapy following tumor resection, the 5-year survival rate for patients with head and neck cancer is at best only 50%. In this study, we examined the therapeutic potential of localized release of diclofenac from electrospun nanofibers generated from poly(D,L-lactide-co-glycolide) polymer. Diclofenac was chosen since anti-inflammatory agents that inhibit cyclooxygenase have shown great potential in their ability to directly inhibit tumor growth as well as suppress inflammation-mediated tumor growth. A mouse resection model of oral carcinoma was developed by establishing tumor growth in the oral cavity by ultrasound-guided injection of 1 million SCC-9 cells in the floor of the mouth. Following resection, mice were allocated into four groups with the following treatment: 1) no treatment, 2) implanted scaffolds without diclofenac, 3) implanted scaffolds loaded with diclofenac, and 4) diclofenac given orally. Small animal ultrasound and magnetic resonance imaging were utilized for longitudinal determination of tumor recurrence. At the end of 7 weeks following tumor resection, 33% of mice with diclofenac-loaded scaffolds had a recurrent tumor, in comparison to 90%-100% of the mice in the other three groups. At this time point, mice with diclofenac-releasing scaffolds showed 89% survival rate, while the other groups showed survival rates of 10%-25%. Immunohistochemical staining of recurrent tumors revealed a near 10-fold decrease in the proliferation marker Ki-67 in the tumors derived from mice with diclofenac-releasing scaffolds. In summary, the local application of diclofenac in an orthotopic mouse tumor resection model of oral cancer reduced tumor recurrence with significant improvement in survival over a 7-week study period following tumor resection. Local drug release of anti-inflammatory agents should be investigated as a therapeutic option in the prevention of tumor recurrence in oral squamous carcinoma.

Fabrication of electrospun poly(D,L lactide-co-glycolide)80/20 scaffolds loaded with diclofenac sodium for tissue engineering.

BACKGROUND: Adaptation of nanotechnology into materials science has also advanced tissue engineering research. Tissues are basically composed of nanoscale structures hence making nanofibrous materials closely resemble natural fibers. Adding a drug release function to such material may further advance their use in tissue repair. METHODS: In the current study, bioabsorbable poly(D,L lactide-co-glycolide)80/20 (PDLGA80/20) was dissolved in a mixture of acetone/dimethylformamide. Twenty percent of diclofenac sodium was added to the solution. Nanofibers were manufactured using electrospinning. The morphology of the obtained scaffolds was analyzed by scanning electron microscopy (SEM). The release of the diclofenac sodium was assessed by UV/Vis spectroscopy. Mouse fibroblasts (MC3T3) were seeded on the scaffolds, and the cell attachment was evaluated with fluorescent microscopy. RESULTS: The thickness of electrospun nanomats was about 1 mm. SEM analysis showed that polymeric nanofibers containing drug particles formed very interconnected porous nanostructures. The average diameter of the nanofibers was 500 nm. Drug release was measured by means of UV/Vis spectroscopy. After a high start peak, the release rate decreased considerably during 11 days and lasted about 60 days. During the evaluation of the release kinetics, a material degradation process was observed. MC3T3 cells attached to the diclofenac sodium-loaded scaffold. CONCLUSIONS: The nanofibrous porous structure made of PDLGA polymer loaded with diclofenac sodium is feasible to develop, and it may help to improve biomaterial properties for controlled tissue repair and regeneration.

Temporal control of drug release from biodegradable polymer: multicomponent diclofenac sodium releasing PLGA 80/20 rod.

In our previous studies we have reported on the development of diclofenac sodium (DS) releasing rods. However, their drug release profiles were unsatisfactory. To enhance the drug release properties of the implant, we have developed a system whereby various elements can be combined into one implant. Melt extruded, self-reinforced (SR), and sterilized (S) DS-containing SR-PLGA 80/20 billets were combined to produce multicomponent implants with various compositions. These components were basically heat pressed together to form multicomponent rods. Drug release from single component and multicomponent rods was defined using a UV-Vis spectrophotometer. DS was released from individual components within 82-111 days and from multicomponent rods within 50-70 days. Thermal properties were analyzed using differential scanning calorimetry (DSC). The melting temperature (T(m)) of multicomponent implants was about 157 degrees C, change in heat fusion (DeltaH) was 13.3 J/g, and the glass transition temperature (T(g)) was 55.4 degrees C. Mechanical strength was measured for 2 weeks and it decreased from 55 to 15 MPa. In conclusion, by compression molding three components with different release rates it is possible to control the temporal release from multicomponent rods. Released DS concentrations were within range for 49-74 days depending on the fractions of individual components used.

Electrospun biodegradable nanofibrous mats for tissue engineering.

AIMS & METHOD: In this study, a microbial polyester, poly(3-hydroxybutyrate-co- 3-hydroxyvalerate) (PHBV), and its blends were electrospun into PHBV (10% w/v), PHBV (15% w/v), PHBV-PLLA (5% w/v), PHBV-PLGA (50:50) (15% w/v) and PHBV-P(L,DL)LA (5% w/v) fibrous scaffolds for tissue engineering. RESULTS: Various processing parameters affected the morphology and the dimensions of beads formed on the fibers. Concentration was highly influential on fiber properties; as it increased from 5 to 15% (w/v), fiber diameter increased from 284 +/- 133 nm to 2200 +/- 716 nm. Increase in potential (from 20 to 50 kV) did not lead to the expected decrease in fiber diameter. The blends of PHBV with lactide-based polymers led to fibers with less beads and more uniform diameter. The surface porosities for PHBV10, PHBV15, PHBV-PLLA, PHBV-PLGA (50:50) and PHBV-P(L,DL)LA were 38.0 +/- 3.8, 40.1 +/- 8.5, 53.8 +/- 4.2, 50.0 +/- 4.2 and 30.8 +/- 2.7%, respectively. In vitro studies using human osteosarcoma cells (Saos-2) revealed that the electrospun scaffolds promoted cell growth and penetration. Surface modification with oxygen plasma treatment slightly improved the improved the results in terms of cell number increase and significantly improved spreading of the cells. CONCLUSION: All scaffolds prepared by electrospinning have implied significant potential for use in further studies leading to bone tissue engineering applications. The PHBV-PLLA blend appeared to yield the best results regarding cell number increase, their attachment and spreading inside and on the scaffold.

Polymer-based biodegradable drug delivery systems in pain management.

Pain is an unpleasant sensory experience commonly produced by damage to bodily tissues and it is one of the most significant public health problems, because 21.5% of the world population is estimated to suffer from pain. It results in a total loss of more than 165 billion US dollars each year in the United States alone. Pain reflects a mixture of various pathophysiologic, psychologic, and genetic contributions. When undertreated, pain usually results in serious immune and metabolic upset. Therefore, it requires wide understanding and intensive effort for a better management. Currently, pain control is limited by the modest efficiency of the used drugs, the serious side effects of these drugs, and the inefficacy of conventional drug administration. By the introduction of the technology of biodegradable controlled-release devices into clinical practice, pain control not only benefits from these novel methods for a better delivery of various drugs, but the side effects of the drugs are reduced because use of the devices improves patient compliance. Biodegradable controlled-release devices are polymer-based devices that are designed to deliver drugs locally in a predesigned manner. Recently, there was a high interest in developing these devices for the delivery of different drugs used for pain control. This paper first highlights the dimensions and basics of the problem of pain. Then, it presents an overview of the biodegradable polymers that are used in drug delivery systems and summarizes the studies carried out on these systems in the field of pain management. We refer to our experience in developing a device for multimodal drug delivery, including the use of nanotechnology. Future perspectives are also presented.